These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38392926)

  • 1. Managing Dry Eye Disease with Novel Medications: Mechanism, Study Validity, Safety, Efficacy, and Practical Application.
    Wong JC; Barak A
    Pharmacy (Basel); 2024 Jan; 12(1):. PubMed ID: 38392926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quintessence of currently approved and upcoming treatments for dry eye disease.
    Patil S; Sawale G; Ghuge S; Sathaye S
    Graefes Arch Clin Exp Ophthalmol; 2024 Aug; ():. PubMed ID: 39215848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Varenicline Solution Nasal Spray: A Review in Dry Eye Disease.
    Frampton JE
    Drugs; 2022 Sep; 82(14):1481-1488. PubMed ID: 36197638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical corticosteroids for dry eye.
    Liu SH; Saldanha IJ; Abraham AG; Rittiphairoj T; Hauswirth S; Gregory D; Ifantides C; Li T
    Cochrane Database Syst Rev; 2022 Oct; 10(10):CD015070. PubMed ID: 36269562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEIBO (perfluorohexyloctane): a novel approach to treating dry eye disease.
    Azhar A; Taimuri MA; Oduoye MO; Sumbal A; Sheikh A; Iqbal A; Ikram A; Waqar E
    Ann Med Surg (Lond); 2024 Sep; 86(9):5292-5298. PubMed ID: 39239035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dry Eye Disease: Focus on Prescription Therapy.
    Marshall LL; Hayslett RL
    Sr Care Pharm; 2023 Jun; 38(6):239-251. PubMed ID: 37231571
    [No Abstract]   [Full Text] [Related]  

  • 7. A review of the first anti-evaporative prescription treatment for dry eye disease: perfluorohexyloctane ophthalmic solution.
    Sheppard JD; Evans DG; Protzko EE
    Am J Manag Care; 2023 Nov; 29(14 Suppl):S251-S259. PubMed ID: 37930231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal Varenicline: Review of a Novel Formulation for the Treatment of Dry Eye Disease.
    Zitko KL; Ladd L; Dougherty TS
    J Pharm Pract; 2023 Dec; 36(6):1448-1453. PubMed ID: 35703427
    [No Abstract]   [Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dry Eye Disease Associated with Meibomian Gland Dysfunction: Focus on Tear Film Characteristics and the Therapeutic Landscape.
    Sheppard JD; Nichols KK
    Ophthalmol Ther; 2023 Jun; 12(3):1397-1418. PubMed ID: 36856980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease.
    White DE; Hendrix LH; Sun L; Tam I; Macsai M; Gibson AA
    J Manag Care Spec Pharm; 2023 Jan; 29(1):69-79. PubMed ID: 36030415
    [No Abstract]   [Full Text] [Related]  

  • 12. The efficacy and safety of varenicline nasal spray for the management of dry eye signs: a systematic review and meta-analysis.
    Bashrahil B; Taher N; Alzahrani Z; Alnabihi A; Aldahlawi A; Alkhathlan M; Alghamdi S
    BMC Ophthalmol; 2023 Jul; 23(1):319. PubMed ID: 37452334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loteprednol Etabonate for the Treatment of Dry Eye Disease.
    Beckman K; Katz J; Majmudar P; Rostov A
    J Ocul Pharmacol Ther; 2020 Sep; 36(7):497-511. PubMed ID: 32391735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Punctal occlusion for dry eye syndrome.
    Ervin AM; Law A; Pucker AD
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD006775. PubMed ID: 28649802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comprehensive Review of the Clinical Trials Conducted for Dry Eye Disease and the Impact of the Vehicle Comparators in These Trials.
    Nichols KK; Evans DG; Karpecki PM
    Curr Eye Res; 2021 May; 46(5):609-614. PubMed ID: 33238774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addressing excessive evaporation: an unmet need in dry eye disease.
    Karpecki PM; Nichols KK; Sheppard JD
    Am J Manag Care; 2023 Oct; 29(13 Suppl):S239-S247. PubMed ID: 37844320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of Perfluorohexyloctane Eye Drops on Tear Film Thickness in Patients with Mild to Moderate Dry Eye Disease: A Randomized Controlled Clinical Trial.
    Schmidl D; Bata AM; Szegedi S; Aranha Dos Santos V; Stegmann H; Fondi K; Krösser S; Werkmeister RM; Schmetterer L; Garhöfer G
    J Ocul Pharmacol Ther; 2020 Apr; 36(3):154-161. PubMed ID: 31895638
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%.
    Sheppard JD; Donnenfeld ED; Holland EJ; Slonim CB; Solomon R; Solomon KD; McDonald MB; Perry HD; Lane SS; Pflugfelder SC; Samudre SS
    Eye Contact Lens; 2014 Sep; 40(5):289-96. PubMed ID: 25083776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, adherence and discontinuation in varenicline solution nasal spray clinical trials for dry eye disease.
    Hauswirth SG; Kabat AG; Hemphill M; Somaiya K; Hendrix LH; Gibson AA
    J Comp Eff Res; 2023 Jun; 12(6):e220215. PubMed ID: 37096956
    [No Abstract]   [Full Text] [Related]  

  • 20. A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: The MYSTIC study.
    Quiroz-Mercado H; Hernandez-Quintela E; Chiu KH; Henry E; Nau JA
    Ocul Surf; 2022 Apr; 24():15-21. PubMed ID: 34920097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.